The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
Obama K. Acta Haematol. 2015 Jun 11;134(4):229-230. [Epub ahead of print]/
Biosimilar filgrastim (Zarzio®) vs Lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with myeloma and lymphoma: A single center experience.
Marchesi F et al. Leuk Lymphoma. 2015 Jun 23:1-12. [Epub ahead of print].
Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials.
Liu X et al. Onco Targets Ther. 2015 Jun 15;8:1459-69. doi: 10.2147/OTT.S84828. eCollection 2015.
High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for “de-novo” multiple myeloma patients: a phase II study.
Musso M et al. Biol Blood Marrow Transplant. 2015 Jun 19. pii: S1083-8791(15)00413-9. doi: 10.1016/j.bbmt.2015.06.011. [Epub ahead of print].
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R et al. J Clin Oncol. 2015 Jun 8. pii: JCO.2014.58.7618. [Epub ahead of print].